Electrochemoterapy With Bleomycin for the Treatment of Unresectable Pancreatic Cancer

Inclusion Criteria: * Radiologic confirmation of locally advanced pancreatic cancer by at least contrast enhanced CT of chest and abdomen (with the upper abdomen scanned according to a dedicated 3mm slice multiphase pancreatic tumor protocol), performed maximum 4 weeks prior to the procedure * Cytohistological diagnosis of pancreatic cancer * Age \> 18 and \< 80 * Stable disease after chemotherapy (no tumor progression, no oncomarkers (Carbohydrate Antigen 19-9 \[CA 19-9\] or Carcinoembryonic antigen \[CEA\]) increase * Performance Status 0 sec. ECOG (Eastern Cooperative Oncology Group) * Written informed consent Exclusion Criteria: * Resectable pancreatic cancer as assessed by multidisciplinary meeting * Stage IV disease * Patients receiving fenitoin, phosphofenitoin or living vaccines * Pregnancy * Progressive disease (either dimensional and not only by stage) * \< 18 years old and \> 80